A study on the risk and economic burden of common malignant tumor due to type 2 diabetes mellitus
10.19485/j.cnki.issn1007-0931.2017.08.002
- VernacularTitle:常见恶性肿瘤归因2型糖尿病风险及医疗经济负担研究
- Author:
Ru-Ying HU
1
;
Jin PAN
;
Hai-Bin WU
;
Wei-Wei GONG
;
Meng WANG
Author Information
1. 浙江省疾病预防控制中心
- Keywords:
Key word: Malignant tumor;
Type 2 diabetes;
Population attributable risk;
Economic burden
- From:
Journal of Preventive Medicine
2017;29(8):762-765
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate risk and the direct economic burden of malignant tumor due to type 2 diabetes mellitus. Methods Combing the data of chronic disease surveillance, follow-up and the fifth health service investigation, we calculated the population attributable risk and the direct economic burden for malignant tumor due to type 2 diabetes mellitus in order to estimate the direct economic burden for tumor caused by type 2 diabetes mellitus. Results The relative risk was 1.68 (95%CI: 1.68-1.70) for people with type 2 diabetes mellitus to develop the malignant tumor than the people without type 2 diabetes mellitus. The proportions of attributable risk (AR%) and population attributable risk (PAR%) were 40.57% and 2.05%, respectively. Moreover, the annual average hospitalization costs for malignant tumor reached 11 billion CNY, which took part 6.48% of total health service costs. And the direct economic burden for malignant tumor due to type 2 diabetes mellitus was 0.228 billion CNY. In addition, the top two highest population attributable risks were colorectal cancer and liver cancer, while the top three greatest direct economic burdens for malignant tumor or malignant tumor due to type 2 diabetes mellitus were lung cancer, colorectal cancer and stomach cancer. Conclusion From this study, we found that type 2 diabetes mellitus increased the risks of tumor and therefore lead to sharply increasing in medical costs of malignant tumor. In order to decrease the risk of malignant tumor and medical costs, we should pay more attention to the prevention of type 2 diabetes mellitus and the screening of malignant tumor due to type 2 diabetes mellitus.
